Cardiac AI Monitoring and Diagnostics Market Report 2026

The cardiac ai monitoring and diagnostics market size has grown exponentially in recent years. It will grow from $2.14 billion in 2025 to $2.71 billion in 2026 at a compound annual growth rate (CAGR) of 26.3%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increased availability of digital cardiac monitoring devices, growing use of ecg diagnostics in hospitals, expansion of clinical cardiology services, improvements in medical data analytics.

The cardiac ai monitoring and diagnostics market size is expected to see exponential growth in the next few years. It will grow to $6.94 billion in 2030 at a compound annual growth rate (CAGR) of 26.5%. The growth in the forecast period can be attributed to increasing adoption of ai-driven diagnostic tools, rising demand for remote patient monitoring solutions, expansion of personalized cardiac care, growing integration of ai with imaging and biomarkers, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of AI-based ecg interpretation, growing deployment of remote cardiac monitoring platforms, rising use of predictive analytics in cardiology, expansion of wearable AI-enabled cardiac devices, enhanced integration of multimodal cardiac data.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of cardiac AI monitoring and diagnostics in the coming years. Cardiovascular diseases (CVDs) encompass a range of heart and blood vessel conditions, including cerebrovascular disease, coronary heart disease, rheumatic heart disease, and others. Cardiac AI monitoring and diagnostics facilitate early detection, risk evaluation, and personalized treatment of cardiovascular conditions, leading to improved patient outcomes. For example, in August 2025, the National Institutes of Health, a US-based government agency, reported that between 2025 and 2050, the prevalence of cardiovascular diseases is expected to rise by 90%, mortality by 73%, and DALYs by 55%, with deaths increasing from 20.5 million to 35.6 million. Consequently, the rising prevalence of cardiovascular diseases is fueling the cardiac AI monitoring and diagnostics market.

Major companies in the cardiac AI monitoring and diagnostics market are concentrating on developing technology-driven medical devices, such as artificial intelligence-based implantable cardiac monitors, to strengthen their market presence. Artificial intelligence-based implantable cardiac monitors are devices that continuously monitor cardiac function. For example, in May 2023, Biotronik, a Germany-based cardiovascular biomedical research and technology company, announced that the US Food and Drug Administration (FDA) had approved the BIOMONITOR IV implantable cardiac monitor (ICM). The BIOMONITOR IV ICM incorporates Biotronik's advanced, AI-powered SmartECG algorithm, which features sophisticated algorithms that eliminate 86% of all false detections while preserving 98% of true episodes. This groundbreaking technology enhances detection accuracy for healthcare professionals, reducing false positive alerts and aiding in fast and precise diagnosis of certain cardiac conditions. In addition to SmartECG technology, BIOMONITOR IV is the first ICM capable of differentiating between premature ventricular contractions (PVCs) and premature atrial contractions (PACs).

In June 2024, Anumana, a US-based cardiac diagnostics company, entered into a collaboration with InfoBionic.Ai to advance AI-powered remote cardiac telemetry technology. The partnership is designed to facilitate early detection of cardiac diseases, enhance patient monitoring and outcomes, and promote innovation in cardiac healthcare solutions. InfoBionic.Ai is a US-based technology firm specializing in artificial intelligence solutions for remote cardiac monitoring and diagnostics.

Major companies operating in the cardiac ai monitoring and diagnostics market are Abbott Laboratories, Medtronic plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Boston Scientific Corporation, ZOLL Medical Corporation, Canon Medical Systems Corporation, Biotronik SE & Co. KG, iRhythm Technologies Inc., Tempus Labs Inc., Viz.ai Inc., HeartFlow Inc., Aidoc, Eko Devices Inc., CardioFocus Inc., Circle Cardiovascular Imaging Inc., Ultromics Limited., Cathworks, Medicalgorithmics S.A., Nanox.AI Ltd, Cardiac Insight Inc., CardioSecur GmbH, Cardionomic Inc., HeartSciences, CardioComm Solutions Inc., CardioDiagnostics Inc.

North America was the largest region in the cardiac AI monitoring and diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac ai monitoring and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac ai monitoring and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cardiac AI monitoring and diagnostics market by increasing costs of imported semiconductor chips, medical sensors, imaging components, and advanced computing hardware used in AI-enabled diagnostic and monitoring systems. Healthcare providers and device manufacturers in North America and Europe are most affected due to reliance on globally sourced electronic components, while Asia-Pacific faces cost pressures on device manufacturing and exports. These tariffs are raising equipment procurement costs and slowing technology upgrades in hospitals and diagnostic centers. However, they are also encouraging local manufacturing of medical electronics, regional software development, and increased investment in domestic AI healthcare ecosystems.

The cardiac ai monitoring and diagnostics market research report is one of a series of new reports that provides cardiac ai monitoring and diagnostics market statistics, including cardiac ai monitoring and diagnostics industry global market size, regional shares, competitors with a cardiac ai monitoring and diagnostics market share, detailed cardiac ai monitoring and diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac ai monitoring and diagnostics industry. This cardiac ai monitoring and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac AI monitoring and diagnostics involve the use of artificial intelligence (AI) technologies in cardiology to monitor and identify various cardiovascular conditions. This includes employing advanced algorithms and machine learning techniques to interpret data from cardiac monitoring devices, such as electrocardiograms (ECGs).

The primary categories of cardiac AI monitoring and diagnostics are cardiac diagnostics and cardiac monitoring. Cardiac diagnostics involves the methods and procedures used to detect heart conditions related to abnormal or impaired heart function. The products encompass both software and hardware applied in areas such as ischemic heart diseases or coronary artery disease (CAD), cardiac arrhythmias, ischemic stroke, and others, with end users including hospitals, diagnostic centers, and similar facilities.

The cardiac AI monitoring and diagnostics market consists of revenues earned by entities by providing services such as ST-segment monitoring, arrhythmia detection, heart rate variability analysis, risk stratification, and echocardiogram interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac AI monitoring and diagnostics market also includes sales of echocardiography devices, cardiac MRI and CT analysis, electrocardiogram (ECG) analysis tools, and wearable devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.